top of page

Co-crystal & Salt Screening


Selecting the optimal solid form of an API during early drug development can mitigate the risk of failure later in development.
This can be achieved through polymorph, salt, and cocrystal screening.

 

66427.jpg

1

Co-crystal Screening 

Choose suitable co-formers to design experiments; Co-crystal form identification and characterization; Thermodynamic phase relationship study; Stability and solubility evaluation; Co-crystal form recommendation.

2

Salt Screening

Design various salt-forming experiments according to the physicochemical properties of compound; Salt form identification and characterization; Thermodynamic phase relationship study; Stability and solubility evaluation; Salt type selection and salt form recommendation.
 

3

Polymorph Screening

Design various crystallization conditions according to the physicochemical properties of the compound; Crystal form identification and characterization; Thermodynamic phase relationship stud; Stability and solubility evaluation; Optimal solid form recommendation.

Co-Crystal & Salt Screening.png

Capabilities - Solid Form Screening

Drug Discovery

Focused Form Screening

  • Physiochemical Property

  • Developability assessment

Pre-clinical

Polymorph/Salt/Co-crystal Screening

  • Thermodynamic phase relationship

  • Stability and solubility evaluation

  • Optimal form recommendation

Clinical

Extensive Form Screening

  • Form evaluation

  • Patenting of polymorph/salt

bottom of page